Primary Cardiac Lymphoma: Italian Multicenter Experience
ConditionPrimary Cardiac Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione Italiana Linfomi - ETS
About this trial
The rationale of this study is to provide an overview on PCL (Primary Cardiac Lymphoma) in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.
Eligibility criteria
Qualifiers
Diagnosis of PCL (any histotype) defined as an extranodal lymphoma involving only the heart with possible involvement of the pericardium.
Age ≥18 years.
Diagnosis histologically confirmed. Cytofluorimetry analysis of pericardial fluid showing phenotypic features consistent with a primary cardiac lymphoma is permitted if a biopsy sample is not feasible/available for diagnosis; monoclonality is not accepted as a surrogate for diagnosis.
Date of diagnosis: from 1st January 2000 to 31st December 2020.
Disqualifiers
Secondary cardiac involvement from lymphoma; primary mediastinal lymphoma with pericardial infiltration or other lymphomas with involvement of the pericardium/the heart by contiguity and primary effusion lymphoma are not included in this study.
Patients treated with chemotherapy regimens that did not include an anti-CD20 monoclonal antibody as first-line therapy.
Refuse to sign a written informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
43 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov